COMPANY

Longeveron

HQ: Miami, FL source · longeveron.com ↗ · Southeast

Keywords: cell therapy metabolic syndrome Hypoplastic Left Heart Syndrome Aging Frailty Human ARDS Covid19 Mild Alzheimer's Disease Metabolic Disease Endothelial Dysfunction Alzheimer's Disease Frailty Longeveron Mesenchymal Stem Cells Lomecel-B medicinal signaling cells Allogeneic MSC Allo-hMSCs

Location: Miami, FL · source · Oct 15, 2026

Profile checked Oct 10, 2026

$62.5MRaised (2 yrs)10Trials (company is sponsor)6NIH grants

Timeline

Mar 11, 2026 Raise Private placement: $30M (up to, as announced), announced Mar 11, 2026. Source: SEC filing. source ↗ · Form D filed Mar 25, 2026 SEC Form D ↗
Mar 10, 2026 Raise Private placement: $15M (up to, as announced), announced Mar 10, 2026. Source: SEC filing. source ↗
Aug 11, 2025 Raise Follow-on offering: $17.5M (up to, as announced), announced Aug 11, 2025. Source: company release on GlobeNewswire. source ↗
Dec 1, 2023 Trial start Phase 2: Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial source ↗
Dec 28, 2021 Trial start Phase 2: Lomecel-B Effects on Alzheimer's Disease source ↗
Jun 25, 2021 Trial start II: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. source ↗
Jul 24, 2020 Trial start Phase 1: Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) source ↗
Feb 21, 2018 Trial start Phase 1/Phase 2: Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) source ↗
Jul 6, 2017 Trial start II: Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty source ↗
2016-11 Trial start Phase 1/Phase 2: Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty source ↗
Oct 10, 2016 Trial start Phase 1: Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease source ↗
2015-04 Trial start Phase 1: Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome source ↗
Mar 3, 2014 Trial start Phase 1/Phase 2: AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery source ↗

Funding

Raised: $62.5M. Last 2 years.

Mar 11, 2026 Private placement: $30M (up to, as announced), announced Mar 11, 2026. Source: SEC filing. source ↗ · Form D filed Mar 25, 2026 SEC Form D ↗
Mar 10, 2026 Private placement: $15M (up to, as announced), announced Mar 10, 2026. Source: SEC filing. source ↗
Aug 11, 2025 Follow-on offering: $17.5M (up to, as announced), announced Aug 11, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 10

Record	Title	Phase	Status	Start	Primary completion
NCT04925024	Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.	II	Active, not recruiting	Jun 25, 2021	Jun 30, 2026 (estimated)
NCT04629105	Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)	Phase 1	Unknown status (ClinicalTrials.gov)	Jul 24, 2020	2024-06 (estimated)
NCT05233774	Lomecel-B Effects on Alzheimer's Disease	Phase 2	Completed	Dec 28, 2021	Sep 29, 2023 (actual)
NCT03525418	Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Feb 21, 2018	Jun 30, 2024 (estimated)
NCT02587572	Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial	Phase 2	Withdrawn	Dec 1, 2023	2023-12 (estimated)
NCT02982915	Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty	Phase 1/Phase 2	Completed	2016-11	2021-09 (actual)
NCT03169231	Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty	II	Completed	Jul 6, 2017	Sep 30, 2021 (actual)
NCT02600130	Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease	Phase 1	Completed	Oct 10, 2016	2020-09 (actual)
NCT02398604	Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome	Phase 1	Terminated	2015-04	2019-03 (actual)
NCT02065245	AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery	Phase 1/Phase 2	Completed	Mar 3, 2014	Oct 2, 2019 (actual)

NIH awards 6

Annual award amounts. Total $5.3M.

Jun 24, 2020 NIH award 5R42AG054322-03 FY2020: $435,997 awarded for that fiscal year; activity R42 (STTR); PI HARE, JOSHUA M; recipient as written: LONGEVERON, LLC, MIAMI, FL. A Randomized, Blinded, Placebo-Controlled Clinical Tr source ↗
Mar 30, 2020 NIH award 5R44AG062015-03 FY2020: $1,974,282 awarded for that fiscal year; activity R44 (SBIR); PI OLIVA, ANTHONY ANDREW; recipient as written: LONGEVERON, LLC, MIAMI, FL. A Phase 2b Clinical Trial to Study the Effic source ↗
Jun 11, 2019 NIH award 4R42AG054322-02 FY2019: $465,489 awarded for that fiscal year; activity R42 (STTR); PI HARE, JOSHUA M; recipient as written: LONGEVERON, LLC, MIAMI, FL. A Randomized, Blinded, Placebo-Controlled Clinical Tr source ↗
Apr 26, 2019 NIH award 4R44AG062015-02 FY2019: $1,983,531 awarded for that fiscal year; activity R44 (SBIR); PI OLIVA, ANTHONY ANDREW; recipient as written: LONGEVERON, LLC, MIAMI, FL. A Phase 2b Clinical Trial to Study the Effic source ↗
Sep 18, 2018 NIH award 1R44AG062015-01 FY2018: $283,040 awarded for that fiscal year; activity R44 (SBIR); PI OLIVA, ANTHONY ANDREW; recipient as written: LONGEVERON, LLC, MIAMI, FL. A Phase 2b Clinical Trial to Study the Efficac source ↗
Sep 23, 2017 NIH award 1R42AG054322-01A1 FY2017: $150,000 awarded for that fiscal year; activity R42 (STTR); PI HARE, JOSHUA M; recipient as written: LONGEVERON, LLC, MIAMI, FL. A Randomized, Blinded, Placebo-Controlled Clinical source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-03-25 Raise Private raise (SEC Form D): $15.9M sold of $33.5M offered; issuer “Longeveron Inc.”. Verified from the SEC filing. SEC filing ↗